Martin Vogelbaum net worth and biography

Martin Vogelbaum Biography and Net Worth

Director of Cara Therapeutics

Martin Vogelbaum is a partner of Rho Ventures. He has more than 17 years of experience investing in the life sciences sector, having been involved with companies at all stages of development, including co-founding more than a half dozen companies.

He joined Rho in 2005 and primarily focuses on investments in biotechnology, biopharmaceuticals and medical devices. Prior to Rho, he was a partner of Apple Tree Partners, a life sciences venture firm focused on early-stage companies. While at Apple Tree, Martin co-founded four start-ups, including Gloucester Pharmaceuticals where he served as interim CEO and chairman.

Martin began his venture capital career in 1993 at Oxford Bioscience Partners, where he served as a general partner. Prior to Oxford, he was a research associate in the bone marrow transplantation unit at Memorial-Sloan Kettering Hospital, where he conducted research in graft-versus-host-disease (GVHD).

Martin received his A.B. in biology and history from Columbia University.

What is Martin Vogelbaum's net worth?: The estimated net worth of Martin Vogelbaum is at least $19,011.93 as of September 14th, 2022. Mr. Vogelbaum owns 44,988 shares of Cara Therapeutics stock worth more than $19,012 as of December 21st. This net worth approximation does not reflect any other investments that Mr. Vogelbaum may own. Learn More about Martin Vogelbaum's net worth.
How do I contact Martin Vogelbaum?: The corporate mailing address for Mr. Vogelbaum and other Cara Therapeutics executives is 107 ELM STREET 9TH FLOOR, STAMFORD CT, 06902. Cara Therapeutics can also be reached via phone at (203) 406-3700 and via email at [email protected]. Learn More on Martin Vogelbaum's contact information.
Has Martin Vogelbaum been buying or selling shares of Cara Therapeutics?: Martin Vogelbaum has not been actively trading shares of Cara Therapeutics over the course of the past ninety days. Most recently, Martin Vogelbaum sold 10,800 shares of the business's stock in a transaction on Wednesday, September 14th. The shares were sold at an average price of $10.28, for a transaction totalling $111,024.00. Following the completion of the sale, the director now directly owns 44,988 shares of the company's stock, valued at $462,476.64. Learn More on Martin Vogelbaum's trading history.
Who are Cara Therapeutics' active insiders?: Cara Therapeutics' insider roster includes Derek Chalmers (CEO), Joana Goncalves (Insider), Jeffrey Ives (Director), Frederique Menzaghi (SVP), Christopher Posner (President, CEO & Director), Thomas Reilly (CFO), Scott Terrillion (Insider), and Martin Vogelbaum (Director). Learn More on Cara Therapeutics' active insiders.
Are insiders buying or selling shares of Cara Therapeutics?: In the last year, insiders at the biopharmaceutical company sold shares 6 times. They sold a total of 60,503 shares worth more than $33,858.03. The most recent insider tranaction occured on May, 2nd when CEO Christopher Posner sold 3,936 shares worth more than $2,952.00. Insiders at Cara Therapeutics own 3.1% of the company. Learn More about insider trades at Cara Therapeutics.
Information on this page was last updated on 5/2/2024.

Martin Vogelbaum Insider Trading History at Cara Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/14/2022	Sell	10,800	$10.28	$111,024.00	44,988
6/7/2021	Sell	8,640	$13.05	$112,752.00	28,800
11/17/2020	Sell	6,000	$16.09	$96,540.00	14,400

Martin Vogelbaum Buying and Selling Activity at Cara Therapeutics

Cara Therapeutics Company Overview

Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

Today's Range

Now: $0.42

$0.34

$0.46

50 Day Range

MA: $0.29

$0.25

$0.42

2 Week Range

Now: $0.42

$0.23

$1.15

Volume

5,343,930 shs

Average Volume

858,401 shs

Market Capitalization

$23.18 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.64

Did You See Trump’s Bombshell Exec. Order 001?

From Banyan Hill Publishing | Ad

Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minutes of stepping into the Oval Office...

I put all the details together for you here — but please hurry.